{"product_id":"elv-porters-five-forces-analysis","title":"Elevance Health Inc. (ELV): 5 FORCES Analysis [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Michael Porter Five Forces analysis of Elevance Health, Inc. gives you a detailed, research-based view of supplier pressure, customer power, rivalry, substitutes, and entry barriers, with direct links to the company's 45.2 million members, \u003cstrong\u003e$197.6 billion\u003c\/strong\u003e of FY 2025 operating revenue, \u003cstrong\u003e90.0%\u003c\/strong\u003e benefit expense ratio, \u003cstrong\u003e$71.7 billion\u003c\/strong\u003e Carelon revenue, \u003cstrong\u003e340.7 million\u003c\/strong\u003e adjusted scripts, and the \u003cstrong\u003e$935 million\u003c\/strong\u003e Q1 2026 regulatory accrual. You'll learn how regulation, Medicare and Medicaid dynamics, digital tools, and scale shape strategy, margins, and competitive risk.\u003c\/p\u003e\u003ch2\u003eElevance Health, Inc. - Porter's Five Forces: Bargaining power of suppliers\u003c\/h2\u003e\n\u003cp\u003eThe bargaining power of suppliers is high for Elevance Health because hospitals, physicians, pharmacy partners, clinical vendors, and regulators can push claim costs up faster than the company can fully reprice plans. The clearest signs are the \u003cstrong\u003e90.0%\u003c\/strong\u003e FY 2025 benefit expense ratio, the \u003cstrong\u003e93.5%\u003c\/strong\u003e Q4 2025 ratio, and the \u003cstrong\u003e$935 million\u003c\/strong\u003e Q1 2026 regulatory accrual, all of which show outside parties still shape cost outcomes.\u003c\/p\u003e\n\n\u003cp\u003eProvider and drug channel pressure is the core issue. When hospitals and physicians raise reimbursement demands, Elevance feels it directly through higher medical claims. The jump in the FY 2025 benefit expense ratio from 2024 by \u003cstrong\u003e150 basis points\u003c\/strong\u003e, and the Q4 2025 increase of \u003cstrong\u003e110 basis points\u003c\/strong\u003e year over year, show that supplier-side costs remained difficult to control. This matters because Elevance operates on large revenue volume, including \u003cstrong\u003e$197.6 billion\u003c\/strong\u003e in FY 2025 revenue, so even small cost changes can move margins. CarelonRx processed \u003cstrong\u003e340.7 million\u003c\/strong\u003e adjusted scripts in FY 2025, which means drug supply partners and pharmacy networks are essential to both continuity of service and cost management.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eReported figure\u003c\/td\u003e\n\u003ctd\u003eWhat it says about supplier power\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2025 benefit expense ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e90.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMedical and pharmacy suppliers captured more of premium revenue through claims cost.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 2025 benefit expense ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e93.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSupplier pressure intensified late in the year, especially in Medicaid and ACA plans.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCarelonRx adjusted scripts\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e340.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHigh prescription volume makes pharmacy channels critical to operations.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCarelon revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$71.7 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eScale helps, but the \u003cstrong\u003e4.8%\u003c\/strong\u003e adjusted operating margin shows limited room to absorb supplier cost increases.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2026 operating revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$49.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLarge scale helps spread fixed costs, but does not remove supplier pricing pressure.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2026 regulatory accrual\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$935 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRegulatory counterparties also influence cash and margin, reducing flexibility in supplier negotiations.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eMedical cost inflation matters because it shows suppliers can still raise realized costs inside Medicaid and ACA plans. Elevance said FY 2025 medical trends pushed the full-year benefit expense ratio to \u003cstrong\u003e90.0%\u003c\/strong\u003e, which means claims consumed most of premium revenue. In Q4 2025, the ratio reached \u003cstrong\u003e93.5%\u003c\/strong\u003e, a level that suggests the company had little room to offset cost growth through pricing alone. That is important in academic analysis because it shows supplier power is not just about contract terms; it also shows up in actual claims settlement, utilization patterns, and drug spend. Even with Q1 2026 operating revenue of \u003cstrong\u003e$49.5 billion\u003c\/strong\u003e, the company still carried a \u003cstrong\u003e12.8%\u003c\/strong\u003e operating expense ratio, with the \u003cstrong\u003e$935 million\u003c\/strong\u003e regulatory accrual adding another layer of cost pressure.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHospitals and physicians can influence unit costs through reimbursement rates and utilization patterns.\u003c\/li\u003e\n \u003cli\u003ePharmacy benefit partners matter because \u003cstrong\u003e340.7 million\u003c\/strong\u003e adjusted scripts depend on stable networks and formulary management.\u003c\/li\u003e\n \u003cli\u003eClinical vendors and care delivery partners can raise service costs without giving Elevance full pricing control.\u003c\/li\u003e\n \u003cli\u003eGovernment agencies act like powerful counterparties when compliance actions create direct cash and margin charges.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eScale helps, but it does not cancel supplier power. Carelon revenue rose \u003cstrong\u003e33%\u003c\/strong\u003e to \u003cstrong\u003e$71.7 billion\u003c\/strong\u003e in FY 2025, and CarelonRx script volume increased \u003cstrong\u003e7%\u003c\/strong\u003e, yet Carelon's adjusted operating margin still fell \u003cstrong\u003e100 basis points\u003c\/strong\u003e to \u003cstrong\u003e4.8%\u003c\/strong\u003e. That combination shows higher volume does not automatically create pricing power over suppliers. It can also deepen dependence on vendor networks, care management systems, and payment infrastructure. Elevance is spending about \u003cstrong\u003e$1 billion\u003c\/strong\u003e a year on digital and AI capabilities, which suggests the company is trying to reduce friction and improve administrative efficiency rather than relying on supplier concessions.\u003c\/p\u003e\n\n\u003cp\u003eTechnology vendors and workforce inputs also carry real weight. Over \u003cstrong\u003e60,000\u003c\/strong\u003e employees now use internal AI tools, and the Sydney Health AI assistant reached \u003cstrong\u003e22 million\u003c\/strong\u003e commercial members. That expands dependence on cloud services, software platforms, and implementation partners. Elevance plans to extend the assistant to Medicare members in late 2026, which should deepen that dependency further. The company's internal AI tools reduced prior authorization denials by nearly \u003cstrong\u003e70%\u003c\/strong\u003e, which is a sign that Elevance is trying to lower administrative supplier friction. In practical terms, this means the company is not controlling suppliers directly; it is using technology to make supplier interactions cheaper and faster.\u003c\/p\u003e\n\n\u003cp\u003eRegulatory inputs also add leverage. CMS's intent to suspend new enrollment in certain Medicare Advantage plans, announced in February 2026 and extended to May 30, 2026, shows that government counterparties can affect operating economics in a way similar to a supplier with strong bargaining power. Elevance booked the \u003cstrong\u003e$935 million\u003c\/strong\u003e accrual in Q1 2026, which hit margins and cash usage immediately. Even though the company reaffirmed at least \u003cstrong\u003e$5.5 billion\u003c\/strong\u003e of FY 2026 operating cash flow, that capital must absorb compliance costs before it can support supplier negotiation, network redesign, or system investment. For academic work, this is a clear example of how supplier power in health insurance extends beyond providers and pharmacies to the regulatory environment that shapes the cost base.\u003c\/p\u003e\u003ch2\u003eElevance Health, Inc. - Porter's Five Forces: Bargaining power of customers\u003c\/h2\u003e\n\u003cp\u003eThe bargaining power of customers is high for Elevance Health, Inc. Members, employers, and government buyers can switch coverage, pressure pricing, and demand better service when value weakens. That power shows up in membership volatility, margin pressure, and the company's heavy focus on retention, plan quality, and service experience.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCustomer-power signal\u003c\/th\u003e\n\u003cth\u003eEvidence\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMembership switching\u003c\/td\u003e\n\u003ctd\u003eHealth Benefits membership fell \u003cstrong\u003e1.1%\u003c\/strong\u003e in FY 2025 to \u003cstrong\u003e45.2 million\u003c\/strong\u003e; medical members recovered only to \u003cstrong\u003e45.4 million\u003c\/strong\u003e in Q1 2026.\u003c\/td\u003e\n \u003ctd\u003eCustomers can leave when pricing or service value weakens, so retention is a core revenue driver.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment buyer leverage\u003c\/td\u003e\n\u003ctd\u003eCMS enrollment restrictions led to a \u003cstrong\u003e$935 million\u003c\/strong\u003e Q1 2026 accrual and management centralized government business in March 2026.\u003c\/td\u003e\n \u003ctd\u003ePublic buyers can change enrollment, pricing, and profitability quickly.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlan comparison\u003c\/td\u003e\n\u003ctd\u003eMembers in \u003cstrong\u003e4+ star\u003c\/strong\u003e Medicare plans rose to \u003cstrong\u003e53%\u003c\/strong\u003e in 2026 from \u003cstrong\u003e40%\u003c\/strong\u003e in 2025.\u003c\/td\u003e\n \u003ctd\u003eCustomers compare quality, so better ratings matter for choice and retention.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice sensitivity\u003c\/td\u003e\n\u003ctd\u003eFY 2025 benefit expense ratio was \u003cstrong\u003e90.0%\u003c\/strong\u003e; Q4 2025 reached \u003cstrong\u003e93.5%\u003c\/strong\u003e; Q1 2026 improved to \u003cstrong\u003e86.8%\u003c\/strong\u003e.\u003c\/td\u003e\n \u003ctd\u003eElevance has limited room to absorb customer price pressure without hurting margins.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService experience\u003c\/td\u003e\n\u003ctd\u003eThe digital assistant reached \u003cstrong\u003e22 million\u003c\/strong\u003e commercial members, and internal AI tools cut prior authorization denials by nearly \u003cstrong\u003e70%\u003c\/strong\u003e.\u003c\/td\u003e\n \u003ctd\u003eLower friction improves loyalty and weakens the customer's ability to demand concessions.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eMembers can switch and exit when the value proposition slips. Health Benefits membership declined by \u003cstrong\u003e1.1%\u003c\/strong\u003e in FY 2025 to \u003cstrong\u003e45.2 million\u003c\/strong\u003e, mainly because of Medicaid attrition. That is direct proof that customers are not locked in. The base recovered only to \u003cstrong\u003e45.4 million\u003c\/strong\u003e medical members in Q1 2026, which means Elevance still has to defend scale instead of relying on loyalty. The company also expects Medicare Advantage membership to fall in the high teens percentage range in FY 2026 because of the CMS enrollment freeze. When access can change that fast, customers hold real bargaining power.\u003c\/p\u003e\n\n\u003cp\u003eGovernment buyers press hard because they buy in large blocks and can reshape economics through policy and contract terms. Elevance centralized its government business under one leader in March 2026 because Medicare, Medicaid, and federal solutions are tied together and heavily negotiated. The CMS enrollment suspension and the \u003cstrong\u003e$935 million\u003c\/strong\u003e Q1 2026 accrual show how one public buyer can affect revenue and earnings in a single quarter. Medicaid competitive pressure was also cited as a driver of margin compression and membership attrition. FY 2025 operating revenue rose \u003cstrong\u003e13%\u003c\/strong\u003e to \u003cstrong\u003e$197.6 billion\u003c\/strong\u003e, but adjusted diluted EPS fell \u003cstrong\u003e8.3%\u003c\/strong\u003e to \u003cstrong\u003e$30.29\u003c\/strong\u003e, which shows that buyers can capture much of the economic benefit.\u003c\/p\u003e\n\n\u003cp\u003ePlan quality drives choice because customers compare ratings, benefits, and access. Elevance improved the share of members in \u003cstrong\u003e4+ star\u003c\/strong\u003e Medicare plans to \u003cstrong\u003e53%\u003c\/strong\u003e in 2026 from \u003cstrong\u003e40%\u003c\/strong\u003e in 2025. That helps, but it also shows customers are paying attention to relative value. The company expects Medicare Advantage membership pressure in the high teens percentage range after the enrollment freeze, so losing trust or rating momentum has a direct cost. Q1 2026 benefit expense ratio improved to \u003cstrong\u003e86.8%\u003c\/strong\u003e from \u003cstrong\u003e90.0%\u003c\/strong\u003e in FY 2025, which means the company still has to manage costs carefully to keep products attractive.\u003c\/p\u003e\n\n\u003cp\u003eCost pressure returns to buyers when medical loss ratios rise and pricing flexibility narrows. Elevance posted a \u003cstrong\u003e93.5%\u003c\/strong\u003e benefit expense ratio in Q4 2025 and ended FY 2025 at \u003cstrong\u003e90.0%\u003c\/strong\u003e, leaving little room to absorb customer resistance. Q1 2026 improved to \u003cstrong\u003e86.8%\u003c\/strong\u003e, and EPS reached \u003cstrong\u003e$12.58\u003c\/strong\u003e, supported by about \u003cstrong\u003e$1.00\u003c\/strong\u003e per share of non-recurring investment income. That means earnings strength did not come from aggressive pricing power. With \u003cstrong\u003e45.4 million\u003c\/strong\u003e medical members and \u003cstrong\u003e$49.5 billion\u003c\/strong\u003e of quarterly revenue in Q1 2026, even small enrollment losses can affect results.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicaid members can switch when state contracts or benefits become less attractive.\u003c\/li\u003e\n \u003cli\u003eMedicare Advantage members can move if plan ratings, premiums, or network access weaken.\u003c\/li\u003e\n \u003cli\u003eEmployers can rebid coverage and push for lower unit costs.\u003c\/li\u003e\n \u003cli\u003eGovernment programs can freeze enrollment or tighten reimbursement rules.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eService experience shapes demand because healthcare customers care about friction. Elevance's digital assistant reached \u003cstrong\u003e22 million\u003c\/strong\u003e commercial members, and the company plans to extend it to Medicare members in late 2026. Internal AI tools cut prior authorization denials by nearly \u003cstrong\u003e70%\u003c\/strong\u003e, which matters because delays and denials are direct pain points for members and employer clients. More than \u003cstrong\u003e60,000\u003c\/strong\u003e employees use those tools, showing that Elevance is scaling service responsiveness to defend loyalty. Carelon Services is also expanding risk-based capabilities to manage a larger share of total healthcare spending, which reflects demand for more integrated and less fragmented care.\u003c\/p\u003e\n\u003ch2\u003eElevance Health, Inc. - Porter's Five Forces: Competitive rivalry\u003c\/h2\u003e\n\u003cp\u003eCompetitive rivalry for Elevance Health is high because it is being squeezed in Medicaid, challenged by integrated peers in services, and pushed by Medicare quality competition. The numbers show slower revenue growth, higher benefit costs, and a business that has to compete through execution, not just price.\u003c\/p\u003e\n\n\u003cp\u003eMedicaid pressure is the clearest sign of rivalry. Competition in Medicaid was explicitly cited as a cause of margin compression and membership attrition, and FY 2025 membership fell \u003cstrong\u003e1.1%\u003c\/strong\u003e to \u003cstrong\u003e45.2 million\u003c\/strong\u003e. The benefit expense ratio, which is the share of premium revenue spent on medical claims, rose to \u003cstrong\u003e90.0%\u003c\/strong\u003e for the full year and \u003cstrong\u003e93.5%\u003c\/strong\u003e in Q4 2025. That tells you pricing and member mix were under pressure. Q1 2026 revenue increased only \u003cstrong\u003e1.5%\u003c\/strong\u003e to \u003cstrong\u003e$49.5 billion\u003c\/strong\u003e, which is modest for a company of this size. Even so, Elevance raised FY 2026 adjusted diluted EPS guidance to at least \u003cstrong\u003e$26.75\u003c\/strong\u003e from \u003cstrong\u003e$25.50\u003c\/strong\u003e, showing it still expects to defend earnings through operating execution.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eRivalry area\u003c\/th\u003e\n\u003cth\u003eEvidence\u003c\/th\u003e\n\u003cth\u003eCompetitive meaning\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicaid managed care\u003c\/td\u003e\n\u003ctd\u003eFY 2025 membership fell \u003cstrong\u003e1.1%\u003c\/strong\u003e to \u003cstrong\u003e45.2 million\u003c\/strong\u003e; benefit expense ratio reached \u003cstrong\u003e90.0%\u003c\/strong\u003e for FY 2025 and \u003cstrong\u003e93.5%\u003c\/strong\u003e in Q4 2025\u003c\/td\u003e\n\u003ctd\u003eRivals are forcing weaker pricing power and higher medical cost pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegrated health services\u003c\/td\u003e\n\u003ctd\u003eCarelon revenue rose \u003cstrong\u003e33%\u003c\/strong\u003e to \u003cstrong\u003e$71.7 billion\u003c\/strong\u003e in FY 2025 and \u003cstrong\u003e7.9%\u003c\/strong\u003e to \u003cstrong\u003e$18.0 billion\u003c\/strong\u003e in Q1 2026, while adjusted operating margin slipped to \u003cstrong\u003e4.8%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eGrowth is strong, but peers in integrated care are also compressing margins\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare quality\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e53%\u003c\/strong\u003e of members were in \u003cstrong\u003e4+ star\u003c\/strong\u003e Medicare plans in 2026, up from \u003cstrong\u003e40%\u003c\/strong\u003e in 2025; CMS enrollment freeze and a projected high-teens MA membership decline hit FY 2026\u003c\/td\u003e\n\u003ctd\u003eQuality ratings are tied directly to enrollment, so rivals can win or lose members through performance scores\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeadership and talent\u003c\/td\u003e\n\u003ctd\u003eElevance named leaders from Optum and Humana on March 31, 2026, and expanded CFO Mark Kaye's oversight to Carelon in February 2026\u003c\/td\u003e\n\u003ctd\u003eTop talent is moving between major competitors, which shows rivalry is strategic, not just operational\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital allocation\u003c\/td\u003e\n\u003ctd\u003eQ1 2026 repurchases totaled \u003cstrong\u003e3.7 million\u003c\/strong\u003e shares for \u003cstrong\u003e$1.1 billion\u003c\/strong\u003e at an average price of \u003cstrong\u003e$304.68\u003c\/strong\u003e, with \u003cstrong\u003e$5.6 billion\u003c\/strong\u003e of authorization left\u003c\/td\u003e\n\u003ctd\u003eBuybacks and dividends are part of the competitive response because investors still compare execution across peers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eCarelon versus integrated peers is the second major rivalry channel. Carelon revenue rose \u003cstrong\u003e33%\u003c\/strong\u003e to \u003cstrong\u003e$71.7 billion\u003c\/strong\u003e in FY 2025 and another \u003cstrong\u003e7.9%\u003c\/strong\u003e to \u003cstrong\u003e$18.0 billion\u003c\/strong\u003e in Q1 2026, but adjusted operating margin still slipped to \u003cstrong\u003e4.8%\u003c\/strong\u003e. That pattern matters because it shows Elevance is competing against health services players that can grow quickly while still dealing with margin pressure. The company's March 2026 hiring from Optum and Humana is a strong signal that those firms are direct benchmarks. Carelon Services is also expanding risk-based capabilities to manage a higher proportion of total healthcare spending, which means the fight is not just over members. It is also over the care-management layer that controls utilization, cost, and service coordination.\u003c\/p\u003e\n\n\u003cp\u003eQuality and ratings are another front in the rivalry. Elevance said \u003cstrong\u003e53%\u003c\/strong\u003e of members were in \u003cstrong\u003e4+ star\u003c\/strong\u003e Medicare plans in 2026, up from \u003cstrong\u003e40%\u003c\/strong\u003e in 2025, so plan quality is clearly being used as a competitive tool. Even with that improvement, the company faced a CMS enrollment freeze and a projected high-teens decline in MA membership for FY 2026. Q1 2026 adjusted diluted EPS of \u003cstrong\u003e$12.58\u003c\/strong\u003e beat estimates by \u003cstrong\u003e$1.69\u003c\/strong\u003e, helped by about \u003cstrong\u003e$1.00\u003c\/strong\u003e per share of non-recurring investment income, but rivals will also be trying to show short-term earnings resilience. The share price rebounded about \u003cstrong\u003e34%\u003c\/strong\u003e from March lows by June 1, 2026, which shows investors are watching competitive execution closely. Better ratings help, but they do not remove rivalry when those ratings translate directly into enrollment.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eMedicaid rivalry forces Elevance to protect membership through network design, service quality, and pricing discipline.\u003c\/li\u003e\n\u003cli\u003eCarelon's growth shows the company is competing in health services, not just insurance, so the battlefield is wider than premium revenue.\u003c\/li\u003e\n\u003cli\u003eMedicare star ratings affect enrollment, so quality has become a direct competitive weapon.\u003c\/li\u003e\n\u003cli\u003eTalent moves from Optum and Humana show that leadership capability is part of rivalry and can shape strategy.\u003c\/li\u003e\n\u003cli\u003eCapital returns matter because the company must reward shareholders while still funding growth, operations, and margin repair.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eLeadership shifts show how serious the competition is. Elevance centralized government business, named a new Carelon Health president from Optum, and brought in a Carelon growth chief from Humana, all on March 31, 2026. Those hires show that the market is competing for managers who know how to run large, integrated health businesses. FY 2025 operating revenue reached \u003cstrong\u003e$197.6 billion\u003c\/strong\u003e, but adjusted diluted EPS still fell \u003cstrong\u003e8.3%\u003c\/strong\u003e to \u003cstrong\u003e$30.29\u003c\/strong\u003e, which makes the internal changes look like a response to pressure rather than a sign of comfort. Management's framing of 2026 as execution and repositioning also fits a high-rivalry market: the company has to reorganize while it grows.\u003c\/p\u003e\n\n\u003cp\u003eCapital allocation is part of the fight too. Elevance repurchased \u003cstrong\u003e3.7 million\u003c\/strong\u003e shares for \u003cstrong\u003e$1.1 billion\u003c\/strong\u003e in Q1 2026 at an average price of \u003cstrong\u003e$304.68\u003c\/strong\u003e and still had \u003cstrong\u003e$5.6 billion\u003c\/strong\u003e of authorization remaining at March 31, 2026. It also reaffirmed at least \u003cstrong\u003e$2.3 billion\u003c\/strong\u003e of full-year 2026 repurchases and raised its quarterly dividend to \u003cstrong\u003e$1.72\u003c\/strong\u003e per share for Q2 2026. Those actions support shareholder returns, but they also show the company must keep generating cash while competing on price, quality, service, and membership retention. Operating cash flow guidance of at least \u003cstrong\u003e$5.5 billion\u003c\/strong\u003e suggests Elevance still has resources to keep fighting, which is why rivalry stays high even at its scale.\u003c\/p\u003e\u003ch2\u003eElevance Health, Inc. - Porter's Five Forces: Threat of substitutes\u003c\/h2\u003e\n\u003cp\u003eThe main substitute threat for Elevance Health, Inc. is not just another health insurer. It is any digital, clinical, or government-backed option that lets members solve coverage, care, or pharmacy needs without using the traditional payer workflow.\u003c\/p\u003e\n\n\u003cp\u003eDigital self-service is a real substitute because it removes the need for a live service representative in routine cases. Sydney Health's AI assistant reached \u003cstrong\u003e22 million\u003c\/strong\u003e commercial members in December 2025, and Elevance Health, Inc. plans to extend it to Medicare members in late 2026. That matters because a larger share of questions about benefits, costs, and care access can now be handled in-app instead of through call centers or paper-based processes.\u003c\/p\u003e\n\n\u003cp\u003eThe company is backing that shift with scale. More than \u003cstrong\u003e60,000\u003c\/strong\u003e employees already use internal AI tools, and those tools cut prior authorization denials by nearly \u003cstrong\u003e70%\u003c\/strong\u003e. Elevance Health, Inc. is also spending about \u003cstrong\u003e$1 billion\u003c\/strong\u003e a year on digital and AI capabilities. In Porter's terms, that is both a defensive move and evidence that technology-based self-service is a substitute for older administrative channels.\u003c\/p\u003e\n\n\u003cp\u003eHome care and primary care are also becoming substitutes for the traditional payer-only model. Carelon Health is now led by a new president focused on clinical strategy across primary and home care, which shows that Elevance Health, Inc. is building services that can replace parts of the classic insurance interaction. Carelon Services is expanding risk-based capabilities to manage a larger share of total healthcare spending, so the company is moving closer to care navigation and care delivery rather than staying only in claims administration.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eSubstitute source\u003c\/th\u003e\n\u003cth\u003eWhat it replaces\u003c\/th\u003e\n\u003cth\u003eWhy it matters for Elevance Health, Inc.\u003c\/th\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital self-service\u003c\/td\u003e\n\u003ctd\u003eCall centers, manual benefit checks, paper workflows\u003c\/td\u003e\n \u003ctd\u003e22 million commercial members already use the AI assistant, so routine service demand is moving into the app\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome and primary care\u003c\/td\u003e\n\u003ctd\u003ePayer-only coordination and fragmented care navigation\u003c\/td\u003e\n \u003ctd\u003eCarelon Health and Carelon Services are shifting the business toward clinical management and risk-based delivery\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutomated pharmacy navigation\u003c\/td\u003e\n\u003ctd\u003eManual prior authorization and prescription support\u003c\/td\u003e\n \u003ctd\u003e70% lower prior authorization denials show that digital tools are replacing paperwork-heavy processing\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlternative member experiences\u003c\/td\u003e\n\u003ctd\u003eLower-service or harder-to-use plan options\u003c\/td\u003e\n \u003ctd\u003eBetter ratings, easier access, and more integrated care can pull members away even when coverage is similar\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment-backed plan options\u003c\/td\u003e\n\u003ctd\u003eSome Medicare Advantage and Medicaid demand\u003c\/td\u003e\n \u003ctd\u003eCMS actions and plan design changes can redirect enrollment away from certain products\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003ePharmacy navigation shows the same pattern. CarelonRx handled \u003cstrong\u003e340.7 million\u003c\/strong\u003e adjusted scripts in FY 2025, but the navigation role around those prescriptions is increasingly being absorbed by digital tools. Since \u003cstrong\u003e22 million\u003c\/strong\u003e commercial members already use Sydney Health, many routine prescription and coverage questions can bypass traditional channels. The substitute threat here is less about replacing insurance outright and more about replacing the administrative touchpoints that make insurance expensive and slow.\u003c\/p\u003e\n\n\u003cp\u003eMember experience also drives substitution. Elevance Health, Inc.'s 2026 Medicare star mix improved to \u003cstrong\u003e53%\u003c\/strong\u003e of members in 4+ star plans from \u003cstrong\u003e40%\u003c\/strong\u003e in 2025. That is important because quality, access, and ease of use can redirect members toward plans that feel simpler or more reliable. If members can get better digital access or better care coordination elsewhere, they may switch even when the underlying premium or benefit structure is similar.\u003c\/p\u003e\n\n\u003cp\u003eThe growth data shows this pressure in the numbers. Q1 2026 operating revenue rose only \u003cstrong\u003e1.5%\u003c\/strong\u003e to \u003cstrong\u003e$49.5 billion\u003c\/strong\u003e while medical membership stood at \u003cstrong\u003e45.4 million\u003c\/strong\u003e. FY 2025 membership declined \u003cstrong\u003e1.1%\u003c\/strong\u003e to \u003cstrong\u003e45.2 million\u003c\/strong\u003e, mainly because of Medicaid attrition. That pattern suggests substitution is showing up as slower growth and mix pressure, not as a sharp collapse in demand.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDigital self-service reduces dependence on traditional service staff and claims support.\u003c\/li\u003e\n \u003cli\u003eHome care and primary care models pull value away from payer-only administration.\u003c\/li\u003e\n \u003cli\u003eAutomated pharmacy tools replace manual approval and navigation steps.\u003c\/li\u003e\n \u003cli\u003eQuality competition creates switching pressure even when products look similar.\u003c\/li\u003e\n \u003cli\u003eGovernment and plan design changes can move members toward other coverage paths.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eRegional and government options add another layer of substitute pressure. CMS enrollment suspension for certain Medicare Advantage plans, along with the expectation of a high-teens decline in Medicare Advantage membership in FY 2026, shows how quickly demand can be redirected. Elevance Health, Inc. recorded a \u003cstrong\u003e$935 million\u003c\/strong\u003e accrual in Q1 2026 for regulatory exposure, which shows how changes in policy can alter where members enroll and which products they prefer.\u003c\/p\u003e\n\n\u003cp\u003eEven with that pressure, the business still expects at least \u003cstrong\u003e$5.5 billion\u003c\/strong\u003e in operating cash flow and at least \u003cstrong\u003e$26.75\u003c\/strong\u003e in FY 2026 adjusted EPS. But those results now have to compete with alternative coverage routes such as Medicaid, ACA plans, Medicare Advantage, and employer-sponsored self-service. As those options improve, the substitute threat rises because members can satisfy the same need for coverage or care access through different channels.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eSubstitute pressure point\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003cth\u003eStrategic effect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSydney Health adoption\u003c\/td\u003e\n\u003ctd\u003e22 million commercial members\u003c\/td\u003e\n\u003ctd\u003eMoves routine service away from human channels\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternal AI usage\u003c\/td\u003e\n\u003ctd\u003e60,000 employees\u003c\/td\u003e\n\u003ctd\u003eSpeeds internal automation and reduces manual work\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior authorization improvement\u003c\/td\u003e\n\u003ctd\u003eNearly 70% fewer denials\u003c\/td\u003e\n\u003ctd\u003eShows digital tools are replacing manual process friction\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCarelonRx scale\u003c\/td\u003e\n\u003ctd\u003e340.7 million adjusted scripts\u003c\/td\u003e\n\u003ctd\u003ePharmacy navigation is being reshaped by automation\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMembership base\u003c\/td\u003e\n\u003ctd\u003e45.4 million members\u003c\/td\u003e\n\u003ctd\u003eEven small substitution shifts affect a very large base\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\u003ch2\u003eElevance Health, Inc. - Porter's Five Forces: Threat of new entrants\u003c\/h2\u003e\n\u003cp\u003eThe threat of new entrants is low. Elevance Health, Inc. has scale, regulation, capital depth, and data-driven operations that a new insurer or health services platform would struggle to match without years of investment and execution risk.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eBarrier\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eElevance Health, Inc. data\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScale\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$197.6 billion\u003c\/strong\u003e FY 2025 operating revenue, \u003cstrong\u003e45.2 million\u003c\/strong\u003e members at year-end 2025, \u003cstrong\u003e45.4 million\u003c\/strong\u003e medical members in Q1 2026\u003c\/td\u003e\n\u003ctd\u003eA new entrant would need massive enrollment and revenue before it could spread fixed costs across a large base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulation\u003c\/td\u003e\n\u003ctd\u003eCMS sanctions on certain Medicare Advantage plans, \u003cstrong\u003e$935 million\u003c\/strong\u003e Q1 2026 accrual, expected high-teens MA membership decline in FY 2026\u003c\/td\u003e\n\u003ctd\u003eRules can change access and earnings quickly, raising both legal and financial risk for new firms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital\u003c\/td\u003e\n\u003ctd\u003eAt least \u003cstrong\u003e$5.5 billion\u003c\/strong\u003e FY 2026 operating cash flow guidance, \u003cstrong\u003e$6.7 billion\u003c\/strong\u003e repurchase authorization at year-end 2025, \u003cstrong\u003e$5.6 billion\u003c\/strong\u003e remaining authorization at March 31, 2026\u003c\/td\u003e\n\u003ctd\u003eEntry requires large upfront funding for technology, compliance, reserves, and growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuality and trust\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e53%\u003c\/strong\u003e of members in 4+ star Medicare plans, up from \u003cstrong\u003e40%\u003c\/strong\u003e in 2025\u003c\/td\u003e\n\u003ctd\u003eQuality scores affect enrollment and trust, and new entrants start without that record\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegration and data\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$71.7 billion\u003c\/strong\u003e Carelon revenue in FY 2025, \u003cstrong\u003e$18.0 billion\u003c\/strong\u003e in Q1 2026, \u003cstrong\u003e340.7 million\u003c\/strong\u003e adjusted scripts through CarelonRx\u003c\/td\u003e\n\u003ctd\u003eIntegrated services and dense data improve underwriting, service design, and cost control\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eScale creates a wall\u003c\/h3\u003e\n\u003cp\u003eElevance Health, Inc. operates at a size that new entrants cannot copy quickly. FY 2025 operating revenue reached \u003cstrong\u003e$197.6 billion\u003c\/strong\u003e, and the company ended 2025 with \u003cstrong\u003e45.2 million\u003c\/strong\u003e members, rising to \u003cstrong\u003e45.4 million\u003c\/strong\u003e medical members in Q1 2026. That scale matters because health insurance rewards large risk pools, lower unit costs, and stronger negotiating power with providers and vendors. Elevance also ran \u003cstrong\u003e$71.7 billion\u003c\/strong\u003e of Carelon revenue and processed \u003cstrong\u003e340.7 million\u003c\/strong\u003e adjusted scripts through CarelonRx, which adds more operating reach. A new entrant would need deep capital, broad distribution, claims infrastructure, and years of member acquisition before it could even approach this footprint.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$197.6 billion\u003c\/strong\u003e revenue gives Elevance room to spread fixed costs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e45.4 million\u003c\/strong\u003e medical members improve pricing and risk pooling.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e340.7 million\u003c\/strong\u003e scripts show a pharmacy platform that is hard to match.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRegulation blocks entrants\u003c\/h3\u003e\n\u003cp\u003eHealth insurance is one of the most regulated industries in the United States, and Elevance Health, Inc. shows why that matters. CMS's notice of sanctions on certain Medicare Advantage plans and the company's \u003cstrong\u003e$935 million\u003c\/strong\u003e Q1 2026 accrual show that compliance errors can have immediate profit consequences. Elevance also expects a high-teens percentage decline in MA membership in FY 2026 because of the enrollment freeze, which proves that regulators can reshape market access quickly. FY 2025 adjusted diluted EPS fell \u003cstrong\u003e8.3%\u003c\/strong\u003e to \u003cstrong\u003e$30.29\u003c\/strong\u003e even as revenue grew \u003cstrong\u003e13%\u003c\/strong\u003e to \u003cstrong\u003e$197.6 billion\u003c\/strong\u003e, so the business already faces strain from oversight and margin pressure. A new entrant would have to survive those shocks without an incumbent's balance sheet or operating history.\u003c\/p\u003e\n\n\u003ch3\u003eCapital and cash flow matter\u003c\/h3\u003e\n\u003cp\u003eEntry into managed care and health services takes cash long before it produces profit. Elevance Health, Inc. reaffirmed at least \u003cstrong\u003e$5.5 billion\u003c\/strong\u003e in FY 2026 operating cash flow, repurchased \u003cstrong\u003e3.7 million\u003c\/strong\u003e shares for \u003cstrong\u003e$1.1 billion\u003c\/strong\u003e in Q1 2026, and paid a \u003cstrong\u003e$1.72\u003c\/strong\u003e quarterly dividend for Q2 2026. It also had \u003cstrong\u003e$5.6 billion\u003c\/strong\u003e of remaining share repurchase authorization at March 31, 2026 and \u003cstrong\u003e$6.7 billion\u003c\/strong\u003e at year-end 2025. That tells you the incumbent model throws off enough cash to fund growth, compliance, reserves, and shareholder returns at the same time. A new entrant would need to finance all of those demands before it reaches scale, which raises the hurdle sharply.\u003c\/p\u003e\n\n\u003ch3\u003eBrand and quality barriers help\u003c\/h3\u003e\n\u003cp\u003eQuality scores matter because employers, members, and regulators use them as a trust signal. Elevance Health, Inc. increased its share of members in 4+ star Medicare plans to \u003cstrong\u003e53%\u003c\/strong\u003e from \u003cstrong\u003e40%\u003c\/strong\u003e in 2025, which strengthens its position in a market where reputation affects enrollment. Q1 2026 adjusted diluted EPS of \u003cstrong\u003e$12.58\u003c\/strong\u003e beat estimates by \u003cstrong\u003e$1.69\u003c\/strong\u003e, and the stock rebounded about \u003cstrong\u003e34%\u003c\/strong\u003e from March lows by June 1, 2026, both signs of confidence in the incumbent. A new entrant would need to build that credibility while also securing provider networks, pharmacy relationships, and member trust. In health care, those relationships take time, and time is a barrier.\u003c\/p\u003e\n\n\u003ch3\u003eIntegration increases entry cost\u003c\/h3\u003e\n\u003cp\u003eElevance Health, Inc. has made its operating model harder to copy by tying insurance, Carelon, and government business more tightly together. On March 31, 2026, the company assigned new leaders to Carelon Health, Carelon growth, and government solutions, showing that integration is now part of the strategy. Carelon revenue of \u003cstrong\u003e$71.7 billion\u003c\/strong\u003e in FY 2025 and \u003cstrong\u003e$18.0 billion\u003c\/strong\u003e in Q1 2026 shows how services now support the core benefits business. The company's internal AI tools are used by more than \u003cstrong\u003e60,000\u003c\/strong\u003e employees and have reduced prior authorization denials by nearly \u003cstrong\u003e70%\u003c\/strong\u003e, which is a practical efficiency gain, not just a tech claim. With \u003cstrong\u003e45.4 million\u003c\/strong\u003e members and \u003cstrong\u003e340.7 million\u003c\/strong\u003e adjusted scripts, Elevance has data density that new entrants cannot buy overnight.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44600308859029,"sku":"elv-porters-five-forces-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/elv-porters-five-forces-analysis.png?v=1740169453","url":"https:\/\/dcf-model.com\/fr\/products\/elv-porters-five-forces-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}